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108The evidence relating blood pressure to salt intake in humans originates from population studies and randomized clinical trials
of interventions on dietary salt intake. Estimates frommeta-analyses of trials in normotensive subjects generally are similar to
estimates derived from prospective population studies (11.7 mm Hg increase in systolic blood pressure per 100-mmol incre-
ment in 24-hour urinary sodium). This estimate, however, does not translate into an increased risk of incident hypertension
in subjects consuming a high salt diet. Prospective studies relating health outcomes to 24-hour urinary sodium excretion pro-
duced inconsistent results. Taken together, available evidence does not support the current recommendations of a generalized
and indiscriminate reduction of salt intake at the population level, although the blood pressure-lowering effect of dietary
sodium restriction might be of value in hypertensive patients.
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Consideration of the role of salt (NaCl) in the pathogenesis
and treatment of essential hypertension is one of the
over-riding research themes both in experimental and clin-
ical medicine.2-4 Few issues in medicine have received
more attention and raised more controversy. Pro-
tagonists of a generalized restriction of sodium intake
made extrapolations from epidemiologic studies of
cardiovascular morbidity in relation to usual blood
pressure.5 In this article, we critically review available ev-
idence concerning role of sodium in blood pressure regu-
lation and as predictor of cardiovascular complications.
Sodium and Hypertension
Physiological Considerations
Sodium has a critical role in extracellular volume regula-
tion and being of fundamental importance in cellular
function across virtually all organ systems. Sodium is the
“skeleton” of extracellular fluid and ensures adequate
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Advances in Chronic Kidney Disease, Volperfusion.2,6 Under normal conditions, a physiological
decrease in blood volume, resulting from reduction in
sodium intake, induces the release of renin from the
kidney, thus producing angiotensin II, and the release
from the pituitary of vasopressin. These 2 hormones
are potently vasoactive, constricting blood vessels
around the remaining volume. Their other important
physiological actions include limiting fluid loss through
the kidneys, stimulating water intake through drinking,
and stimulating the release of aldosterone from adrenals
to decrease sodium loss from the kidneys. The 3
hormones, renin, vasopressin, and aldosterone, therefore,
work in concert physiologically to combat a decrease in
blood volume, or hypovolemia, because of extracellular
dehydration. Conversely, under conditions of salt excess,
thirst-induced increased fluid intake would lead, initially,
to an increased blood volume, which would persist only
for a short time until the excretion of water and sodium,
through the urine, and would restore the circulating vol-
ume and osmolality to their normal set point in response
to the reduced release of the hormones vasopressin and
aldosterone.
Total body salt and extracellular volume are closely
linked and controlled by kidney salt excretion and dietary
salt intake only.7 Blunted kidney salt excretion in this
concept results in an expansion of the extracellular fluid
volume, which can induce a rise in blood pressure, de-
noted as the salt sensitivity of blood pressure.8 This hy-
pothesis is supported by the fact that monogenic forms
of hypertension involve kidney channels and transporters
that predispose the body to extracellular sodium reten-
tion.9,10 Moreover, there are available data that sodium
appetite clearly involves complex brain circuitry, similar
to other homeostatic behavioral drives such as hunger
and thirst, where angiotensin II and aldosterone are
primarily peripheral signals.6 However, the body sodium
content is on average normal in patients with benign
essential hypertension likely at the expense of an increased
blood pressure.11 Moreover, recent experimental findings
demonstrate that salt can be stored in a newly discovered
subcutaneous interstitial compartment by binding to poly-
anionic proteoglycans and glycosaminoglycans without
commensurate water retention.12 Although it is widely22, No 2 (March), 2015: pp 108-115
Sodium and Cardiovascular Outcome 109accepted that blood pressure responses to changes in die-
tary salt intake are heterogeneous,13,14 unfortunately there
is no practical clinical test to assess sodium sensitivity in
individual subjects. Lack of changes in urinary sodium
excretion in 38 US studies conducted over 46 years (1957
to 2003)15 and in 13 surveys carried out in the United
Kingdom over 25 years (1984 to 2008)16 support the
concept that sodium intake is difficult to manipulate and
is regulated to maintain the concentration of extracellular
and serum sodium within a narrow range. Thus, the stim-
ulation of the renin-angiotensin system and the secondary
increase in sodium intake may be the result of CKD and
not the notion that higher sodium intake contributes to
CKD.
Sodium Intake and Blood Pressure
The evidence relating blood pressure to salt intake in hu-
mans originates from population studies17 and random-
ized clinical trials of interventions on dietary salt intake.1
Studies in inbred rodents exposed at extremes of sodium
loading with or without salt-retaining hormones cannotCLINICAL SUMMARY
 Sodiumhas a critical role in extracellular volume regulation
and being of fundamental importance in cellular function
across virtually all organ systems.
 The evidence relating blood pressure to salt intake in
humans originates from population studies and
randomized clinical trials of interventions on dietary salt
intake, showing small effect size (2 mm Hg per
100 mmol of sodium).1
 Prospective studies relating health outcomes to 24-hour
urinary sodium excretion have produced inconsistent re-
sults.
 Available evidence does not support the current
recommendations of a generalized and indiscriminate
reduction of salt intake at the population level.be extrapolated to humans.
Observational Cross-
sectional Studies
Across 52 “INTERSALT”
centers, the median 24-hour
urinary sodium excretion
ranged from 0.2 to
242.1 mmol.17 When the rela-
tion between blood pressure
and salt intake (assessed by
the 24-hour urinary sodium
excretion) was studiedwithin
each of the 52 INTERSALT
centers, with adjustments for
sex and age applied, a posi-
tive association was found in
39 of the 52 centers, signifi-
cant in 15 (P, .05); a negative
association was noticed in 13
centers, significant in 2. Analyses across centers of median
blood pressure and the prevalence of hypertension in rela-
tion to median sodium excretion showed a positive associ-
ation when all 52 centers were included but not when 4
populations with low sodium values were excluded. After
standardization for sex and age and with adjustments for
body mass index and alcohol intake applied, the cross-
sectionally assessed age-related increase in systolic and
diastolic blood pressure was significantly steeper with
higher sodium excretion.17
Prospective Studies
In our longitudinal population-based study,18 a group of
1499 participants had blood pressure and sodium excre-
tion measured at baseline and after 6.1 years of follow-
up. The annual increases in blood pressure averaged
0.37 mm Hg systolic and 0.47 mm Hg diastolic
(P , .001), but on average the 24-hour urinary sodium
excretion did not change over time. However, in
multivariable-adjusted analyses of individual partici-pants, a 100-mmol increment in 24-hour sodium excretion
was associated with a significant 1.71 mm Hg increase in
systolic blood pressure (P , .001), without concomitant
change in diastolic blood pressure.18
Intervention Studies
The intervention studies of sodium reduction are often con-
ducted with sodium reduction used “on top” of other life-
style modification. A typical example is the Trial of
Nonpharmacologic Interventions in the Elderly
(TONE19). The study attempted to determine whether
weight loss or reduced sodium intake is effective in the
treatment of older persons (aged 60-80 years) with hyper-
tension. The authors randomized 585 obese participants
to reduced sodium intake, weight loss, both, or usual
care and the 390 nonobese participants to reduced
sodium intake or usual care. The primary end point
included high blood pressure after discontinuation of the
blood pressure-lowering medication at entry (190/110,
170/100, and 150/90 mm Hg at 1, 2, and 3 visits—not
adjudicated), resuming drug treatment, inability towithdraw treatment, and
cardiovascular complica-
tions (angina, myocardial
infarction, stroke, heart fail-
ure, and coronary revascu-
larization). After a median
follow-up of 29 months
(range 15-36 months), the
composite outcome
occurred less frequently
among those assigned vs
not allocated to reduced so-
dium intake (hazard ratio
[HR] 0.69; 95% confidence
interval [CI], 0.59-0.81;
P , .001).19 The mean
change in blood pressure19
for participants assigned to
sodium reduction alone
was –3.4 mm Hg systolicand –1.9 mm Hg diastolic and for participants assigned
to combined intervention of sodium reduction and weight
loss –5.3 and –3.4 mm Hg, respectively (P , .001 for com-
parisons to usual-care group).
The TONE investigators qualified their results as having
important implications.19 The study, however, has to be
interpreted within the context of its limitations, including
selection of adherent and well-educated patients (only
11.1% of prescreened patients were finally randomized),
uncertain blinding, confounding of intervention on so-
dium by weight reduction, and increase in physical activ-
ity. The primary end point included soft and hard end
points. There was no difference between sodium-
restricted and control patients in the incidence of cardio-
vascular events (44 [12.9%] vs 57 [16.7%]; P ¼ .2419).
Several overviews1,20-23 addressed the effects of reducing
salt intake on blood pressure. A large meta-analysis of low
vs high sodium diets1 included 167 studies. In White hy-
pertensive patients and normotensive subjects, blood pres-
sure on the sodium-restricted diet decreased by 5.48 mm
Stolarz-Skrzypek and Staessen110Hg systolic (95% CI, 4.4-6.53 mm Hg; P , .0001) and
2.75 mm Hg for diastolic (95% CI, 2.17-3.34 mm Hg;
P , .00001) and by 1.27 mm Hg systolic (95% CI, 0.66-
1.88 mm Hg; P ¼ .0001) and 0.05 mm Hg diastolic (95%
CI, –0.42 to 0.51; P ¼ .85), respectively. The average trial
duration was only 4 weeks.1 Sodium reduction resulted
in significant increases (P , .001) in renin, aldosterone,
noradrenaline, adrenaline, cholesterol, and triglyceride.1
Estimates from meta-analyses of salt intervention trials
in normotensive subjects are remarkably similar to the
effect size we observed in our European prospective
population study: a 1.7 mm Hg increase in systolic blood
pressure per 100-mmol change in the 24-hour urinary so-
dium excretion (Fig 1). However, this small increase in
systolic blood pressure did not translate in a higher risk
of hypertension in relation to salt intake as reflected by
baseline 24-hour urinary sodium.18 Indeed, among 2096-100 0 100 200
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Figure 1. Change in systolic blood pressure during follow-
up by deciles of the change in the 24-hour urinary sodium
excretion in the blood pressure cohort (n ¼ 1499). The data
markers are centered on the means in each decile. The ana-
lyses were adjusted for study population, sex, baseline
values of and changes in age, body mass index, alcohol
intake (stopping, no change, and starting coded as –1, 0,
1), 24-hour urinary potassium excretion, use of female sex
hormones (–1, 0, 1), and nonsteroidal anti-inflammatory
drugs (–1, 0, 1), and account for family clusters. Changes
are expressed in absolute units (A) or as percentage changes
(B). The P-values are for linear trend. Dotted lines represent
the regression line and the 95% confidence interval for the
changes in systolic blood pressure across deciles. Repro-
duced with permission from reference.18participants followed up for 6.5 years, the risk of hyper-
tension did not increase across increasing tertiles
(P ¼ .93; Fig 2). In multivariable-adjusted analyses, there
were 187 cases of incident hypertension (27.0%; HR vs
the average risk in the whole study population, 1.00;
95% CI, 0.87-1.16) in the low, 190 cases (26.6%; HR, 1.02;
95% CI, 0.89-1.16) in the medium, and 175 cases (25.4%;
HR, 0.98; 95% CI, 0.86-1.12) in the high sodium excretion
group.18
Other groups reported similar observations.24,25 He and
colleagues24 examined in 128 subjects the effects of a ran-
domized 18-month intervention on salt intake on the inci-
dence of hypertension. During the intervention, the
between-group gradient in 24-hour urinary sodium excre-
tion averaged 33 mmol. After an average of 7 years of
follow-up without any intervention on salt intake, the
multivariable-adjusted odds of hypertension for active
intervention vs control was 0.65,24 but in line with our
findings, it did not reach significance (95% CI, 0.25-1.69;
P ¼ .37). In 1520 middle-aged and elderly Taiwanese,
followed for 7.93 years, there was a J-shaped relation
between the incidence of hypertension (669 cases) and
24-hour urinary sodium excretion.25 Participants who
were in the highest quartile of sodium excretion and
who had a higher than median systolic blood pressure
(116 mm Hg) had a 2.43-fold increased risk of hyperten-
sion compared with those with a lower than median sys-
tolic blood pressure, who were in the lowest quartile of
sodium excretion. A major limitation of this Taiwanese
study is that investigators computed 24-hour sodium
excretion from the duration of sleep and the time of pass-
ing urine in the morning.25
In the recent publication, Mente and coauthors26 re-
ported in the study of 102,216 adults from 18 countries
and 5 continents, a positive but nonuniform association be-
tween estimated sodium excretion and blood pressure.
They found a steep slope for this association among study
participants with sodium excretion of more than 5 g/d, a
modest association among those with sodium excretion
of 3 to 5 g/d, and no significant association among those
with sodium excretion of less than 3 g/d.26Incidence of hypertension
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Figure 2. Kaplan-Meier estimates for the incidence of hyper-
tension by tertiles of the 24-hour urinary sodium excretion at
baseline. Tertiles of the 24-hour urinary sodium excretion
are sex specific based on baseline measurements. Repro-
duced with permission from reference.18
Sodium and Cardiovascular Outcome 111Cardiovascular Mortality and Morbidity in
Relation to Salt Intake
Several prospective studies dealt with the effects of
salt intake on the incidence of hypertension or cardio-
vascular complications, but few18,27-30 based their
assessments on the 24-hour urinary sodium excretion.
Studies Based on 24-Hour Urinary Sodium
Excretion
In the Scottish Heart Health Study,28 24-hour urinary so-
dium excretion only predicted coronary heart disease in
women. The HR for the lowest quintile vs the other quin-
tiles of sodium excretion was 1.16 (95% CI, 1.00-1.33).
One major limitation is that results were only adjusted
for sex.28 However, the results for total and coronary mor-
tality were not significant in either sex.
In a 19-year follow-up study of 3126 Fins,29 the
multivariable-adjusted HRs associated with a 100-mmol
increase in 24-hour urinary sodium were 1.26 (95% CI,
1.06-01.50) for total mortality, 1.45 (95% CI, 1.14-1.84) for
cardiovascular disease, and 1.51 (95%CI, 1.14-2.00) for cor-
onary heart disease. When analyses were stratified by sex,
the HRswere significant only inmen and amongmen only
among overweight men.29 Nevertheless, the authors
concluded that their results provide direct evidence of
the harmful effects of high salt intake in the adult
population.29
Alderman and colleagues27 followed 2937 mild-to-
moderate hypertensive patients for 3.5 years. Myocardial
infarction and the 24-hour urinary sodium excretion at
baselinemeasured after a drug-free interval of 3 to 4weeks
were inversely associated in the total population and in
men but not women.27 In men, the race- and age-
adjusted HR expressing the risk in the lowest vs the high-
est quartile of 24-hour urinary sodium excretion was 4.3
(95% CI, 1.7-10.6).
Cook and colleagues30 analyzed the long-term results
of dietary sodium restriction on cardiovascular outcomes
by combining 10 to 15 years of follow-up of 744 and 2382
participants randomized in the Trials of Hypertension
Prevention (TOHP), phases 1 and 2. Net sodium reduc-
tions during the intervention period (18-48 months) were
44 and 33 mmol/d, respectively. The follow-up for mortal-
ity was 100% but only 77% for morbidity. No information
was available on blood pressure, weight, and sodium
intake during follow-up. With adjustments applied for
trial, clinical site, race, sex, and age, the HRs for interven-
tion vs control were 0.80 (95% CI, 0.51-1.26; P¼ .34) for to-
tal mortality and 0.75 (95% CI, 0.57-0.99; P ¼ .04) for
cardiovascular events.30 The same group later published
a report based on the follow-up of 2275 TOHP controls,
in which there was no association between clinical out-
comes and salt intake, as assessed by repeated 24-hour
urine collections.31 In the most recent report from the
THOP Investigators, among 2275 prehypertensive TOHP
participants characterized by a median of five 24-hour
urine collections (range, 1-7), 193 cardiovascular events
occurred.32 First events included 68 myocardial infarc-
tions, 77 coronary revascularizations, 22 strokes, and 27
cardiovascular deaths.32 In fully adjusted models account-ing for clinic, treatment assignment, demographic vari-
ables, baseline covariables, and changes in weight,
smoking, and exercise, there was a nonsignificant trend
of increasing risk with higher sodium excretion.
Compared with those with sodium excretion ranging
from 3600 mg/d (157 mmol/d) to 4800 mg/d (209 mmol/d),
the risk for those with sodium less than 2300 mg/d was
32% lower (P ¼ .13). When sodium was considered as a
continuous term, risk increased by 17% per 1000 mg/d
(43 mmol/d) increase in sodium, but as for the categorical
analysis, the P value was not formally statistically signifi-
cant (P ¼ .054).32
Our own study18 included 3681 people without cardio-
vascular disease at baseline, all White Europeans, who
were members of families randomly enrolled in the Flem-
ish Study on Genes, Environment, and Health Outcomes
(1985 to 200433) or in the European Project on Genes in
Hypertension (1999 to 200134). During a median follow-
up of 7.9 years, cardiovascular deaths decreased across
increasing tertiles of 24-hour sodium excretion, from 50
deaths in the low (mean, 107 mmol; 2.5 g sodium), 24 in
the medium (mean, 168 mmol; 3.9 g), and 10 in the high
excretion group (mean, 260 mmol; 6.0 g; P , .001), result-
ing in respective death rates of 4.1%, 1.9%, and 0.8%,
respectively (Fig 3). This significant inverse association be-
tween cardiovascular mortality and tertile of sodium
excretion was retained in multivariable analyses (P for
trend ¼ .02), with an HR of 1.56 in the low tertile vs the
overall risk in the whole-study population (P ¼ .04). The
24-hour sodium excretion at baseline did not predict either
total mortality or fatal combined with nonfatal cardiovas-
cular events.18 In keeping with our population data,18 2
cohort studies involving type 135 or type 236 diabetic pa-
tients also reported increased mortality associated with
lower 24-hour urinary sodium excretion.
Studies Based onDietary Recall, Food Frequency
Questionnaires, or Spot Urines
Several investigators applied dietary recall37-42 or food
frequency questionnaires43 to assess salt intake and re-
ported contradictory results. In the first National Health
and Nutrition Examination Survey (NHANES) I, the asso-
ciation between cardiovascular disease and salt intakewas
positive in obese participants38 but was inverse in the
entire sample.39 In a first analysis of the NHANES III
data,40 salt intake was not associated with either all-
cause mortality or incident cardiovascular disease. The
99% confidence intervals of the HRs per 1000 mg of so-
dium intake ranged from 0.86 to 1.04 (P ¼ .11) and from
0.73 to 1.06 (P ¼ .07), respectively. In a re-analysis of the
same NHANES III database,44 Yang and colleagues
concluded that a higher sodium-potassium ratio was asso-
ciated with a significantly increased risk of all-cause mor-
tality and cardiovascular disease and that a higher sodium
intake was associated with higher mortality in the general
population. However, in Yang’s analysis,44 potassium
intake was driving the association between the outcome
and the sodium-to-potassium ratio, and the relations
between outcome and salt intake were not adjusted for
potassium intake. These 2 analyses of the NHANES III
data40,44 highlight how accounting for covariables might
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Figure 3. Kaplan-Meier survival function estimates for cardiovascular (CV) mortality (A) and for all CV events (B) by tertiles of
the 24-hour urinary sodium excretion at baseline. This analysis includes the Outcome Cohort of the Flemish Study on Genes,
Environment, and Health Outcomes/European Project on Genes in Hypertension study. Reproduced with permission from
reference.18
Stolarz-Skrzypek and Staessen112influence results. They also illustrate the lack of
unambiguous evidence and robustness that characterizes
most attempts to relate mortality and morbidity to salt
intake.
O’Donnell and colleagues45 reported observational ana-
lyses of 2 cohorts of high-risk patients (n ¼ 28,880)
included in the Ongoing Telmisartan Alone and in Combi-
nation with Ramipril Global Endpoint Trial46 and Telmi-
sartan Randomized Assessment Study in ACE Intolerant
Subjects With Cardiovascular Disease47 trials. They esti-
mated 24-hour urinary sodium and potassium excretion
from a morning fasting urine sample. The association be-
tween cardiovascular outcomes and salt intake had a J
shape with a nadir at 4 to 5.99 g/d; a sodium excretion of
more than 7 g/d was associated with increased risk of all
cardiovascular events, whereas a sodium excretion of
less than 3 g/d was associated with increased cardiovascu-
lar mortality and hospitalization for congestive heart
failure.45
Meta-Analyses
Taylor and associates48 did a quantitative review of 7
randomized clinical trials that addressed the effect of re-
stricting salt intake on cardiovascular disease: 3 in normo-
tensive volunteers, 2 in hypertensive patients, 1 in a mixed
population of normotensive and hypertensive partici-
pants, and 1 in heart failure. Salt reduction was associated
with reductions in urinary salt excretion between 27 and
39 mmol per 24 hours and reductions in systolic blood
pressure between 1 and 4 mm Hg. Pooled relative risks
(RRs) comparing the intervention with the reference
groups for all-cause mortality were 0.90 (95% CI, 0.58-
1.40; 79 deaths) and 0.96 (95% CI, 0.83-1.11; 565 deaths)
in normotensive and hypertensive participants, respec-
tively.48 Cardiovascular mortality48 was only reported in
2 studies of hypertensive patients. The pooled RR was
nonsignificant (RR, 0.69; 95%CI, 0.45-1.05; 98 cardiovascu-
lar deaths). For cardiovascular morbidity,48 the corre-
sponding RRs were 0.71 (95% CI, 0.42-1.20; 200 events)
and 0.84 (95% CI, 0.57-1.23; 93 events). Salt restriction
increased the risk of all-cause mortality in patients with
heart failure (RR, 2.59; 95% CI, 1.04-6.44; 21 deaths48).Taylor’s analysis produced conclusions at variance with
the results reported by Strazzullo and associates.49 These
investigators reported that the risk of stroke increased by
6% (95% CI, 3%-10%; P ¼ .04) for an increase in sodium
intake as close as possible to 100 mmol/d but in fact
ranging from 44 to 150 mmol/d. A similar trend for cardio-
vascular disease was not significant (119%, 95% CI, –31%
to 107%, P¼.5349). Across the reports included in Strazzul-
lo’s meta-analysis, the methods for assessing salt intake
were not standardized. Studies with exclusively fatal out-
comes were pooled with those including both fatal and
nonfatal events. Moreover, the HRs used in the variance-
weighted meta-regression analysis were not standardized
to the same amount of sodium.49
Recent meta-analysis by Graudal and colleagues50
included data from 23 cohort studies and 2 follow-up
studies of randomized controlled trials. In 274,683 partici-
pants, the risks of all-causemortality or cardiovascular dis-
ease were higher at low and high vs usual sodium intake,
congruent with a U-shaped association between health
outcomes and salt intake.50 The HRs of total mortality
and cardiovascular disease for low vs usual sodium intake
were 1.10 (95% confidence interval, 1.01-1.22) and 1.11
(1.01-1.22), respectively. The corresponding HRs for high
vs usual sodium exposure were 1.16 (1.03-1.30) and 1.12
(1.02-1.24).50
The Prospective Urban Rural Epidemiology Investiga-
tors recently investigated in 101,945 persons from 17 coun-
tries the association between estimated sodium excretion
and the composite of death and cardiovascular out-
comes.51 Compared with an estimated sodium excretion
of 4.00 to 5.99 g/d, a higher estimated sodium excretion
($7.00 g/d) was associated with an increased risk of the
composite outcome of death and major cardiovascular
events (odds ratio, 1.15; 95% CI, 1.02-1.30) and increased
risks of death and major cardiovascular events considered
separately. As compared with the reference range, an esti-
mated sodium excretion that was less than 3.00 g/d was
also associated with an increased risk of the composite
outcome (odds ratio, 1.27; 95% CI, 1.12-1.44).51
The mechanisms underlying the inverse association
between adverse cardiovascular outcomes and salt
Sodium and Cardiovascular Outcome 113intake might be that sodium restriction low enough to
decrease blood pressure also stimulates sympathetic
tone,1,52 attenuates insulin sensitivity,53 activates the
renin-angiotensin system,1 and stimulates aldosterone
secretion.1 The antagonistic nature of these physiological
responses probably antagonizes the blood pressure-
lowering effect of dietary sodium restriction and might
increase rather than weaken the cardiovascular risk.54
Current Recommendations
The American Heart Association is now proposing to
lower sodium intake in the general population to less
than 1500 mg/d by 2020.55 This recommendation is based
on 2 extrapolations. The first is that the small blood pres-
sure decreases, observed in short-term trials of selected
hypertensive patients or normotensive volunteers in
response to varying degrees of sodium restriction, may
also occur in the general population. The second extrapo-
lation is that a shift with few millimeters of mercury in
the blood pressure distribution in the general population
might entail substantial differences in morbidity and mor-
tality and rates of hospitalization. The protagonists of a
generalized ban on salt also do not consider the possible
side effects of an indiscriminate decrease of salt intake1,3
and the doubtful feasibility of a generalized limitation of
salt consumption.56,57 Three recent reports,58-60 using
statistical modeling and a set of complex assumptions,
concluded that modest reductions in dietary salt intake,
in the order of 3 g/d, could substantially reduce
cardiovascular events and medical costs. However, these
projections58-60 ignored the inconsistency of the
association between blood pressure and various indexes
of salt intake in observational studies.61,62 They were
based on far-reaching extrapolations from short-term
intervention trials in normotensive or hypertensive volun-
teers to the general population.1
Recently, Institute of Medicine has examined the avail-
able evidence.63 The Committee found that the modest
blood pressure effect is not a certain surrogate for health
outcomes associated with sodium intake and that effects
on actual morbidity and mortality were measures by
which harm or benefit could be assessed. The Committee
recognized heterogeneity of results among observational
and experimental studies, on the basis of ambient or start-
ing sodium intake. Based on the large body of mostly
observational data, it found that a possibility of harm ex-
isted at the lower (,2300 mg) end and more confidently
at the higher excessive end as well. The committee
declined to identify any target for sodium intake or a
safe range of intakes consistent with optimal human
health.63
Further evidence, including Graudal meta-analysis50
and Prospective Urban Rural Epidemiology data,51 indi-
cates that both extremely high and extremely low sodium
intake is harmful with regard to mortality and cardiovas-
cular morbidity and confirms that the safe level of sodium
intake exists world-wide.
Conclusions
Available evidence does not support the current recom-
mendations of a generalized and indiscriminate reductionof salt intake at the population level. The public should be
properly educated about the pros and cons of a decrease
in sodium intake, in particular if they are healthy, and
left free to opt for the level of salt intake that they feel is
appropriate for them. The recent report for the Institute
of Medicine by providing balanced review represents a
paradigm shifting publication concerning the dietary
sodium guidelines.References
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